459 related articles for article (PubMed ID: 15071769)
21. Rituximab for steroid-dependent nephrotic syndrome.
Beco A; Castro-Ferreira I; Coentrao L; Neto R; Sampaio S; Pestana M
Clin Nephrol; 2010 Oct; 74(4):308-10. PubMed ID: 20875384
[TBL] [Abstract][Full Text] [Related]
22. Rituximab treatment in pediatric patients with steroid-dependent nephrotic syndrome: A tertiary hospital.
Guzmán Morais B; Ordóñez Álvarez FÁ; Santos Rodríguez F; Martín Ramos S; Fernández Novo G
An Pediatr (Engl Ed); 2022 Feb; 96(2):83-90. PubMed ID: 35144901
[TBL] [Abstract][Full Text] [Related]
23. Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome.
Webb H; Jaureguiberry G; Dufek S; Tullus K; Bockenhauer D
Pediatr Nephrol; 2016 Apr; 31(4):589-94. PubMed ID: 26525199
[TBL] [Abstract][Full Text] [Related]
24. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus.
Sinha MD; MacLeod R; Rigby E; Clark AG
Nephrol Dial Transplant; 2006 Jul; 21(7):1848-54. PubMed ID: 16311257
[TBL] [Abstract][Full Text] [Related]
25. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
Ravani P; Bonanni A; Ghiggeri GM
BMJ Open; 2017 Mar; 7(3):e013319. PubMed ID: 28314744
[TBL] [Abstract][Full Text] [Related]
26. New treatment strategies in idiopathic nephrotic syndrome.
Ulinski T; Aoun B
Minerva Pediatr; 2012 Apr; 64(2):135-43. PubMed ID: 22495188
[TBL] [Abstract][Full Text] [Related]
27. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
28. Nephrotic syndrome and rituximab: facts and perspectives.
Haffner D; Fischer DC
Pediatr Nephrol; 2009 Aug; 24(8):1433-8. PubMed ID: 19495800
[TBL] [Abstract][Full Text] [Related]
29. Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome.
Kurosu N; Sugiura H; Iwasaki C; Asamiya Y; Kojima C; Moriyama T; Itabashi M; Tsukada M; Takei T; Ogawa T; Yoshida T; Uchida K; Tsuchiya K; Nitta K
Intern Med; 2009; 48(21):1901-4. PubMed ID: 19881243
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
[TBL] [Abstract][Full Text] [Related]
31. Long-term Successful Treatment of Rituximab for Steroid-resistant Minimal Change Nephrotic Syndrome and Idiopathic Thrombocytopenic Purpura.
Nishikawa M; Shimada N; Kawazoe T; Sawaki R; Ikuta H; Kanzaki M; Fukuoka K; Fukushima M; Asano K
Intern Med; 2020 Apr; 59(7):983-986. PubMed ID: 31866629
[TBL] [Abstract][Full Text] [Related]
32. Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience.
El-Husseini A; El-Basuony F; Mahmoud I; Sheashaa H; Sabry A; Hassan R; Taha N; Hassan N; Sayed-Ahmad N; Sobh M
Nephrol Dial Transplant; 2005 Nov; 20(11):2433-8. PubMed ID: 16204303
[TBL] [Abstract][Full Text] [Related]
33. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial.
Ponticelli C; Edefonti A; Ghio L; Rizzoni G; Rinaldi S; Gusmano R; Lama G; Zacchello G; Confalonieri R; Altieri P
Nephrol Dial Transplant; 1993; 8(12):1326-32. PubMed ID: 8159300
[TBL] [Abstract][Full Text] [Related]
34. Cyclosporin A plus prednisone treatment of steroid-sensitive frequently relapsing nephrotic syndrome in children.
Aksu N; Türker M; Erdoğan H; Ozinel S; Kansoy S
Turk J Pediatr; 1999; 41(2):225-30. PubMed ID: 10770662
[TBL] [Abstract][Full Text] [Related]
35. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
Wang W; Yu QH; Zhang HY; Chu XX; Chen F; Zhang CQ; Zhou YH; Hou M
Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
[TBL] [Abstract][Full Text] [Related]
36. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery.
Sellier-Leclerc AL; Baudouin V; Kwon T; Macher MA; Guérin V; Lapillonne H; Deschênes G; Ulinski T
Nephrol Dial Transplant; 2012 Mar; 27(3):1083-9. PubMed ID: 21810762
[TBL] [Abstract][Full Text] [Related]
37. [Long-term prognosis of patients with steroid-dependent nephrotic syndrome treated with rituximab].
Kamei K; Okada M; Miyazono A; Sato M; Fujimaru T; Ogura M; Ito S
Nihon Jinzo Gakkai Shi; 2013; 55(5):947-55. PubMed ID: 23980480
[TBL] [Abstract][Full Text] [Related]
38. Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials.
Iijima K; Sako M; Kamei K; Nozu K
Pediatr Nephrol; 2018 Sep; 33(9):1449-1455. PubMed ID: 28717938
[TBL] [Abstract][Full Text] [Related]
39. Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children.
Larkins N; Kim S; Craig J; Hodson E
Arch Dis Child; 2016 Apr; 101(4):404-8. PubMed ID: 26289063
[TBL] [Abstract][Full Text] [Related]
40. Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.
Bonanni A; Calatroni M; D'Alessandro M; Signa S; Bertelli E; Cioni M; Di Marco E; Biassoni R; Caridi G; Ingrasciotta G; Bertelli R; Di Donato A; Bruschi M; Canepa A; Piaggio G; Ravani P; Ghiggeri GM
Br J Clin Pharmacol; 2018 Jun; 84(6):1238-1249. PubMed ID: 29436729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
